Literature DB >> 12719567

Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice.

E Brian Flanagan1, Trenton R Schoeb, Gail W Wertz.   

Abstract

Transcription of vesicular stomatitis virus is controlled by the position of a gene relative to the single 3' genomic promoter: promoter-proximal genes are transcribed at higher levels than those in more 5' distal positions. In previous work, we generated viruses having rearranged gene orders. These viruses had the promoter-proximal gene that encodes the nucleocapsid protein, N, moved to the second or fourth position in the genome in combination with the glycoprotein gene, G, moved from its usual promoter-distal fourth position to the first or third position. This resulted in three new viruses identified by the positions of the N and G genes in the gene order: G3N4, G1N4, and G1N2. The viruses G3N4 and G1N4 were attenuated for lethality in mice. In the present study, we addressed the basis of this attenuation by measuring the ability of each of the rearranged viruses to travel to and replicate in the olfactory bulb and brain following intranasal inoculation. In addition, the neuropathogenicity, serum cytokine levels, and immunoglobulin G isotype profiles in infected mice were determined. All the viruses reached the olfactory bulb and brain, but the outcomes of these infections were dramatically different. Viruses N1G4(wt) and G1N2 caused lethal encephalitis in 100% of animals within 7 days postinoculation; however, viruses G3N4 and G1N4 were cleared from the brain by 7 days postinoculation and all animals survived without apparent distress. The viruses differed in the distribution and intensity of lesions produced and the type and levels of cytokines induced. Animals inoculated with N1G4(wt) or G1N2 displayed extensive encephalitis and meningitis and had elevated levels of serum gamma interferon compared to what was seen with G3N4- or G1N4-infected mice. In contrast to what occurred with intranasal inoculation, all four viruses caused lethal encephalitis when administered by direct inoculation to the brain, a route that circumvents the majority of the host immune response, demonstrating that G3N4 and G1N4 were not deficient in their abilities to cause disease in the brain. These findings indicate that gene rearrangement and its consequent alteration of gene expression can, without any other changes, alter the viral spread and cytokine response following intranasal infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719567      PMCID: PMC154046          DOI: 10.1128/jvi.77.10.5740-5748.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  IFN-gamma is not required in the IL-12 response to vesicular stomatitis virus infection of the olfactory bulb.

Authors:  T Komatsu; C S Reiss
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

3.  Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus.

Authors:  C Burkhart; G Freer; R Castro; L Adorini; K H Wiesmüller; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 4.  Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes.

Authors:  K K Conzelmann
Journal:  Annu Rev Genet       Date:  1998       Impact factor: 16.830

5.  Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus.

Authors:  G W Wertz; V P Perepelitsa; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

6.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

7.  Delayed administration of interleukin-12 is efficacious in promoting recovery from lethal viral encephalitis.

Authors:  D D Ireland; T Bang; T Komatsu; C S Reiss
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

8.  Role of the nucleocapsid protein in regulating vesicular stomatitis virus RNA synthesis.

Authors:  H Arnheiter; N L Davis; G Wertz; M Schubert; R A Lazzarini
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

9.  Pathogenicity and immunogenicity for mice of temperature-sensitive mutants of vesicular stomatitis virus.

Authors:  R R Wagner
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

10.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

View more
  14 in total

1.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

2.  Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.

Authors:  David K Clarke; Farooq Nasar; Margaret Lee; J Erik Johnson; Kevin Wright; Priscilla Calderon; Min Guo; Robert Natuk; David Cooper; R Michael Hendry; Stephen A Udem
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

3.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

4.  Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice.

Authors:  Durdica Cekinović; Mijo Golemac; Ester Pernjak Pugel; Jelena Tomac; Luka Cicin-Sain; Irena Slavuljica; Russell Bradford; Sonja Misch; Thomas H Winkler; Michael Mach; William J Britt; Stipan Jonjić
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  Attenuated Infectious Hematopoietic Necrosis Virus with Rearranged Gene Order as Potential Vaccine.

Authors:  Ronan N Rouxel; Carolina Tafalla; Emilie Mérour; Esther Leal; Stéphane Biacchesi; Michel Brémont
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

6.  Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.

Authors:  Ryann C Guayasamin; Tracy D Reynolds; Xin Wei; Mai Fujiwara; Michael D Robek
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

7.  Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.

Authors:  Anthony N van den Pol; John N Davis
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

8.  mRNA cap methylation influences pathogenesis of vesicular stomatitis virus in vivo.

Authors:  Yuanmei Ma; Yongwei Wei; Xiaodong Zhang; Yu Zhang; Hui Cai; Yang Zhu; Konstantin Shilo; Michael Oglesbee; Steven Krakowka; Sean P J Whelan; Jianrong Li
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

9.  Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain.

Authors:  Koray Ozduman; Guido Wollmann; Sebastian A Ahmadi; Anthony N van den Pol
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

10.  Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.

Authors:  J Erik Johnson; Farooq Nasar; John W Coleman; Roger E Price; Ali Javadian; Kenneth Draper; Margaret Lee; Patricia A Reilly; David K Clarke; R Michael Hendry; Stephen A Udem
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.